Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones.

The role of bone as an endocrine organ has gained attention in recent years. Bone-derived factors influence metabolic processes beyond skeletal maintenance. Prior research has shown that osteoblasts and osteocytes secrete proteins with systemic effects. However, the extent to which these proteins function as hormones remains unclear. This gap motivated investigations into osteocalcin and sclerostin. No prior work had resolved whether these proteins act as endocrine hormones. The structural role of bone is well established, but its endocrine functions are still debated. This uncertainty drove the need for a synthesis of current evidence on these bone-derived factors.

This article aims to evaluate the evidence for endocrine functions of sclerostin and osteocalcin. The specific problem is whether these proteins act as hormones outside of bone. The motivation stems from conflicting findings in animal and human studies. Researchers propose that osteocalcin may influence multiple organs. Sclerostin’s role in regulating WNT signaling is well known, but its systemic effects are less clear. The study seeks to clarify whether these proteins have endocrine roles. It also addresses controversies regarding osteocalcin’s non-bone functions. The goal is to summarize current knowledge and identify areas needing further research.

The authors conducted a literature review of animal models and human physiology studies. They analyzed evidence for endocrine functions of sclerostin and osteocalcin. Data sources included peer-reviewed articles and clinical studies. The approach involved synthesizing findings on systemic effects of these proteins. Comparisons were made between paracrine and endocrine roles of the hormones. The review focused on effects in adipose tissue, kidney, and energy homeostasis. Researchers examined controversies surrounding osteocalcin’s non-bone functions. The synthesis highlighted gaps in understanding the full biological roles of these proteins.

Osteocalcin is proposed to regulate multiple organs including pancreas, liver, and adipose tissue. Sclerostin acts on adipocytes and kidney to influence mineral metabolism. Evidence suggests both proteins have endocrine functions beyond bone. Animal studies show osteocalcin affects energy homeostasis and glucose regulation. Sclerostin’s paracrine role in bone is well established, but its systemic effects are debated. Human studies indicate a link between osteocalcin levels and metabolic outcomes. Controversies remain regarding osteocalcin’s role in non-bone tissues. The review highlights the need for further research to clarify these functions.

The authors propose that osteocalcin and sclerostin may function as endocrine hormones. Evidence supports their roles in regulating energy homeostasis and mineral metabolism. The review suggests these proteins act on multiple target organs beyond bone. Sclerostin’s effects on adipocytes and kidney are highlighted as potential endocrine functions. The authors note that controversies remain regarding osteocalcin’s non-bone roles. Current findings are based on animal and human studies. The synthesis indicates a need for further research to confirm these functions. The authors conclude that these bone-derived factors may have broader physiological roles.